This systematic review aimed to evaluate the effectiveness of indirect cold atmospheric plasma (CAP) in disrupting oral and skin microbial biofilms and to investigate whether the reported effects are mainly attributable to acidic pH, plasma-activated liquids, or specific devices and treatment settings. The review followed PRISMA guidelines and was registered on the Open Science Framework. A comprehensive literature search was conducted across major electronic databases. Studies evaluating indirect CAP on in vitro oral and skin microbial biofilms were included. Comparisons were made with untreated controls, non-activated liquids, and conventional antimicrobials. Outcomes were evaluated based on reductions in biofilm viability or biomass using quantitative assays (e.g., CFU, XTT, and Crystal Violet). Thirteen in vitro studies were included. CFU-based outcomes were reported in 11 of 13 studies (84.61%), and all of these studies showed reductions exceeding 5–6 log under specific conditions. Antimicrobial efficacy varied according to exposure time, microbial species, plasma parameters, and treatment settings, while physicochemical analyses indicated that acidic conditions and plasma-activated liquids play a key role. Indirect CAP appears to be a promising non-invasive antimicrobial strategy for managing oral and skin biofilms. However, variability among devices and settings, together with the absence of clinical data, underscores the need for further standardized studies and clinical investigations.
Atrial fibrillation (AF), one of the most prevalent and widespread arrhythmias, has remained a heavy global burden in the past decade and directly influences the quality of human life. It is estimated that AF affects 2–4% of the world’s adult population, and it is predicted to double due to (i) life expectancy increasing and (ii) the rising frequency of undiagnosed cases. Recent studies suggest that the alteration of gut microbiota (GM), known as dysbiosis, could increase the AF risk. Since dysbiosis is a modifiable risk factor, interventions aimed at restabilizing gut eubiosis by diet, probiotics, or prebiotic supplements may represent a promising strategy for AF prevention and/or treatment, although current clinical evidence remains limited. In this scenario, it is very critical to understand which types of GM alterations or metabolites may be involved in the development of atrial AF, as this could open new strategies for managing the pathology. However, many gaps still need to be filled, as it remains unclear how dysbiosis contributes to AF across different populations and no fine characterization of the underlying pathogenic mechanisms is available yet. This review summarizes the last evidence on the association between GM dysbiosis and AF, highlighting the main proposed mechanisms, key microbial genes and metabolites involved, clinical implications and the need for further prospective studies.
Background: The Enterobacteriaceae family is the most heterogeneous group of Gram-negative bacilli, with both environmental and clinical relevance. Although many of these species are part of the normal intestinal microbiota, species such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis are among the most common opportunistic pathogens, frequently responsible for nosocomial infections, including urinary tract infections, bacteraemia, and pneumonia. Based on these concerns, these species are increasingly being studied for their ability to develop antimicrobial resistance, often mediated by extended spectrum β-lactamase or carbapenemase production. The present study aims to analyse the antimicrobial resistance profiles of Enterobacteriaceae isolated from a southern Italian hospital focusing on the species of major clinical importance. Methods: A retrospective analysis was carried out on biological samples collected between 2019 and 2023 at the Microbiology Laboratory of the San Pio Hospital, Vasto (Italy). Eight hundred ninety patients were included, with an average age of 73 years. Bacterial identification was carried out using bacterial culture and biochemical methods, while antimicrobial sensitivity was assessed by using the automated Walk Away System. Results: The most frequently isolated species were Escherichia coli (63.2%), Klebsiella spp. (21.9%), and Proteus spp. (8.8%). All isolates showed resistance to at least one antimicrobial and most to more than four. The highest resistance rates were observed for Cefotaxime (16.0%), followed by Ampicillin (15.6%) and Ciprofloxacin (13.2%). Conclusions: The high prevalence of antimicrobial resistance among clinically relevant Enterobacteriaceae species is a growing clinical challenge. The results of this study, which describe the trend of resistance among Enterobacteriaceae in a local hospital, could help to raise awareness highlighting the urgent need for more advanced diagnostic tools and new therapeutic strategies to treat infections caused by multi-resistant microorganisms.